NCT04322188View on ClinicalTrials.gov

An Observational Study of the Use of Siltuximab (SYLVANT) in Patients Diagnosed With COVID-19 Infection Who Have Developed Serious Respiratory Complications

CompletedOBSERVATIONAL

Enrollment

220

Participants

Timeline

Start Date

March 19, 2020

Primary Completion Date

May 8, 2020

Study Completion Date

May 8, 2020

Conditions

Severe Acute Respiratory Syndrome (ARDS) Secondary to SARS-COV-2 Infection

Interventions

OTHER

this is an observational study. No intervention is applicable; patients are managed as per clinicians' best judgement and best practice

Trial Locations (1)

24127

ASST - Papa Giovanni XXIII, Bergamo

All Listed Sponsors

lead

A.O. Ospedale Papa Giovanni XXIII

OTHER

NCT04322188 - An Observational Study of the Use of Siltuximab (SYLVANT) in Patients Diagnosed With COVID-19 Infection Who Have Developed Serious Respiratory Complications | Biotech Hunter | Biotech Hunter